C. Lagarde et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION IN CONGENITAL ERYTHROPOIETIC PORPHYRIA (GUNTHERS-DISEASE), Annales de dermatologie et de venereologie, 125(2), 1998, pp. 114-117
Introduction. The congenital erythropoietic porphyria (Gunther's disea
se) (CEP) is a rare autosomal recessively metabolic disease due to the
deficit of uroporphyrinogen III cosynthetase, fourth enzyme of the po
rphyrin-heme biosynthesis. This disease is characterized by severe cut
aneous photosensitivity with profond skin lesions, hemolytic anemia an
d excess of uroporphyrin I excretion. The vital prognosis is very bad
and until now, no treatment seems to be efficient. Bone marrow transpl
antation seems to be able to correct the enzymatic deficit that causes
the disease because it is located in the bone marrow. Observation. We
report the case of a four and a half year old girl who received an al
logeneic bone marrow transplantation (BMT) at the age of two. Despite
an encouraging result, the first transplantation failed. A second allo
geneic transplantation was attempted eight months later with the same
HLA identical heterozygous donor and bone marrow engrafment succeeded.
Twenty one months after the second bone mal row transplantation, clin
ical and biological results are still excellent. Discussion. No classi
cal treatment of CEP really proved its efficiency and no one was curat
ive. CEP resulting from an homozygous deficiency in uroporphyrinogen I
II cosynthetase, enzyme that takes part in the porphyrin-heme biosynth
esis which is principaly located in the erythropoietic system of the b
one marrow, substitution of this defective lineage by BMT was a very a
ttractive treatment to correct this anomaly. The first bone marrow tra
nsplantation attempted on an affected child in 1990 in Manchester fail
ed because the patient died of infections complications. After the fai
lure of the first transplantation, our little patient is now healed tw
enty one months after the second BMT and biochemical anomalies are cor
rected. If a long follow up is necessary to appreciate the long-term e
fficiency of this treatment, allogeneic bone marrow transplantation se
ems to cure Gunther's disease and must be proposed as the treatment of
this affection.